title: CMV infection attenuates the disease course in a murine model of multiple sclerosis.
abstract: Recent evidence in multiple sclerosis (MS) suggests that active CMV infection may result in more benign clinical disease. The goal of this pilot study was to determine whether underlying murine CMV (MCMV) infection affects the course of the Theiler's murine encephalitis virus (TMEV) induced murine model of MS. A group of eight TMEV-infected mice were co-infected with MCMV at 2 weeks prior to TMEV infection while a second group of TMEV-infected mice received MCMV two weeks post TMEV. We also used 2 control groups, where at the above time points MCMV was replaced with PBS. Outcome measures included (1) monthly monitoring of disability via rotarod for 8 months; (2) in vivo MRI for brain atrophy studies and (3) FACS analysis of brain infiltrating lymphocytes at 8 months post TMEV infection. Co-infection with MCMV influenced the disease course in mice infected prior to TMEV infection. In this group, rotarod detectable motor performance was significantly improved starting 3 months post-infection and beyond (p≤0.024). In addition, their brain atrophy was close to 30% reduced at 8 months, but this was only present as a trend due to low power (p = 0.19). A significant reduction in the proportion of brain infiltrating CD3+ cells was detected in this group (p = 0.026), while the proportion of CD45+ Mac1+ cells significantly increased (p = 0.003). There was also a strong trend for a reduced proportion of CD4+ cells (p = 0.17) while CD8 and B220+ cell proportion did not change. These findings support an immunomodulatory effect of MCMV infection in this MS model. Future studies in this co-infection model will provide insight into mechanisms which modulate the development of demyelination and may be utilized for the development of novel therapeutic strategies.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America. Pirko@mayo.edu
authors.forename: Istvan
authors.initials: I
authors.lastname: Pirko
authors.forename: Rhonda
authors.initials: R
authors.lastname: Cardin
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: Anne K
authors.initials: AK
authors.lastname: Lohrey
authors.forename: Diana M
authors.initials: DM
authors.lastname: Lindquist
authors.forename: R Scott
authors.initials: RS
authors.lastname: Dunn
authors.forename: Robert
authors.initials: R
authors.lastname: Zivadinov
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Johnson
mesh_terms: D000818:Animals; D001921:Brain / Q000473:pathology; D017252:CD3 Complex / Q000096:biosynthesis; D016827:CD8 Antigens / Q000096:biosynthesis; D003586:Cytomegalovirus Infections / Q000150:complications / Q000628:therapy* / Q000821:virology; D003711:Demyelinating Diseases / Q000821:virology; D004195:Disease Models, Animal; D004660:Encephalitis / Q000821:virology; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D007107:Immune System; D007249:Inflammation; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D051379:Mice; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy / Q000821:virology*; D015203:Reproducibility of Results; D013997:Time Factors
chemical_list: D017252:CD3 Complex; D016827:CD8 Antigens; D017493:Leukocyte Common Antigens